Opportunities Preloader

Please Wait.....

Report

Boehringer Ingelheim International GmbH : Strategic SWOT and PESTLE Analysis - A 360 Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, and Recent Trends

Company Report I 2024-05-10 I 94 Pages I Quaintel Research

Report Summary

Boehringer Ingelheim International GmbH : Strategic SWOT and PESTLE Analysis - A 360 Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, and Recent Trends Report is a comprehensive and easily accessible overview of Boehringer Ingelheim International GmbH's business operations. It provides a detailed analysis of the company's strategic standing, as well as its position in the industry compared to competitors. The report includes several key features to facilitate decision-making and provide insights into the company's performance.

The report begins with in-depth information about Boehringer Ingelheim International GmbH including key insights, business segments, key executives, locations, products and services, historical events, corporate strategy, and management discussions. This section provides a solid foundation for understanding the company's key attributes.

Next, the report assesses Boehringer Ingelheim International GmbH's strategic standing through various analyses. The ESG spotlight evaluates the company's environmental, social, and governance performance, providing insights into its sustainability efforts and ethical practices. The SWOT analysis examines the company's internal strengths and weaknesses, as well as external opportunities and threats. The PESTLE analysis evaluates the external factors impacting the company's operations and market environment. Additionally, By integrating these strategic analyses, the report offers a comprehensive understanding of Boehringer Ingelheim International GmbH's overall strategic standing and supports informed decision-making and strategic planning.

Finally, the report includes recent news and deal activities undertaken by Boehringer Ingelheim International GmbH enhancing awareness of the company's business trends, growth perspectives, and more.

Key Highlights

Boehringer Ingelheim International GmbH operates as a subsidiary of C. H. Boehringer Sohn AG and Co. KG. Boehringer Ingelheim International GmbH operates in the pharmaceuticals segment for humans and animals as well as contract development and manufacturing services. Boehringer Ingelheim International GmbH engages in the research, development, and marketing of drugs for humans and animals. It offers cardiovascular, respiratory, oncology, immunology, metabolic diseases, retinal health, and central nervous system products. The company also offers pharmaceutical products for companion animals and livestock. Additionally, it offers tailor-made contract development and manufacturing services to the biopharmaceutical industry. Founded in 1885, the company is headquartered in Ingelheim am Rhein, Rhineland-Palatinate, Germany.

Boehringer Ingelheim International GmbH in the News:-

- 2024-04-18 - Boehringer Ingelheim introduces NexGard SPECTRA for dogs in India
- 2024-04-09 - Boehringer Ingelheim Biopharmaceuticals China receives approval for supply of EU and US markets
- 2024-02-14 - Jardiance (empagliflozin) now approved in India for the treatment of adults with chronic kidney disease
- 2024-02-01 - Boehringer Ingelheim India earns "Top Employer 2024" accolade for second consecutive year
- 2023-09-20 - Boehringer Ingelheim India joins forces with Pet Practitioners Association of Mumbai (PPAM) and Brihanmumbai Municipal Corporation (BMC) to 'Stop Rabies' in Mumbai

Scope

- Tactical Analysis:- Various strategic frameworks to gain insights into a company's competitive position and operational environment. These analytical tools assist in identifying competitive advantages, potential risks, and areas for improvement and efficiency, enabling companies to make informed tactical decisions.
- Business Strategy:- Contributes to shaping the company's overall direction, goals, and decision-making processes, ensuring long-term success and alignment with stakeholder expectations.
- Company Fundamentals:- These fundamentals offer valuable insights into the company's history, operations, leadership, and geographical presence, aiding in a comprehensive understanding of the organization.
- Competitive Landscape:- An identification of the company's main competitors, providing insights into the competitive landscape it operates in.

Reasons to Buy

- Comprehensive Understanding of the Boehringer Ingelheim International GmbH's internal and external factors through SWOT analysis, PESTLE analysis and Competitors Benchmarking.
- Strive Strategic Decision Making with various analyses and identifying potential customers and suppliers.
- Mitigate Risk with help of thorough analysis of internal and external factors. Furthermore, develop strategies and contingency plans to address these challenges and minimize their impact on business operations.
- Competitive Benchmarking will help to gain a competitive advantage by understanding industry trends, customer preferences, and best practices.
- Valuable insights from the report enable investors and partners to make informed decisions regarding potential Collaborations, Investments, or Partnerships with the company.

Additionally, available deep-dive analysis on the company Boehringer Ingelheim International GmbH:
- Boehringer Ingelheim International GmbH Value Chain Analysis
- Boehringer Ingelheim International GmbH Porter's Five Forces Analysis
- Boehringer Ingelheim International GmbH VRIO Analysis
- Boehringer Ingelheim International GmbH BCG Analysis
- Boehringer Ingelheim International GmbH Segmentation, Targeting and Positioning (STP) Analysis
- Boehringer Ingelheim International GmbH Ansoff Matrix Analysis

Table of Contents
Table of Contents 2
Tables 5
Charts 6
Boehringer Ingelheim International GmbH - Key Company Facts 7
Boehringer Ingelheim International GmbH - Company Description 8
Boehringer Ingelheim International GmbH - Top Executives 9
Boehringer Ingelheim International GmbH - Top Executives Biographies 10
Boehringer Ingelheim International GmbH - Head Office & Locations 12
Head Office - Country 12
Key Subsidiaries 13
Key Joint Ventures 15
Boehringer Ingelheim International GmbH - Products and Services 16
Products 16
Boehringer Ingelheim International GmbH - Historic Events 19
Boehringer Ingelheim International GmbH - Company's Management Discussion 20
Boehringer Ingelheim International GmbH - Company's Mission and Vision 22
Vision 22
Boehringer Ingelheim International GmbH - Corporate Strategy 23
Boehringer Ingelheim International GmbH - Business Description 25
Human Pharmaceuticals 25
Animal Health 26
Biopharmaceutical Contract Manufacturing 26
Other Sales 26
Boehringer Ingelheim International GmbH - ESG Spotlight 27
Environment 27
Social 27
Corporate Governance 28
Boehringer Ingelheim International GmbH - SWOT Analysis 29
Overview 29
Strengths 31
Weaknesses 34
Opportunities 35
Threats 38
Boehringer Ingelheim International GmbH - PESTLE Analysis 40
Overview 40
Political Factors 42
Economic Factors 44
Social Factors 45
Technological Factors 47
Legal Factors 49
Environmental Factors 51
Competing Players 52
Snapshot of Competing Players 53
AstraZeneca Plc 53
Key Company Facts 53
Company Description 53
GSK plc 55
Key Company Facts 55
Company Description 55
Novartis AG 57
Key Company Facts 57
Company Description 57
Pfizer Inc. 59
Key Company Facts 59
Company Description 59
Sanofi SA 61
Key Company Facts 61
Company Description 61
Boehringer Ingelheim International GmbH - In the News 63
18-Apr-2024 - Boehringer Ingelheim introduces NexGard SPECTRA for dogs in India 63
09-Apr-2024 - Boehringer Ingelheim Biopharmaceuticals China receives approval for supply of EU and US markets 66
14-Feb-2024 - Jardiance (empagliflozin) now approved in India for the treatment of adults with chronic kidney disease 68
01-Feb-2024 - Boehringer Ingelheim India earns "Top Employer 2024" accolade for second consecutive year 70
20-Sep-2023 - Boehringer Ingelheim India joins forces with Pet Practitioners Association of Mumbai (PPAM) and Brihanmumbai Municipal Corporation (BMC) to 'Stop Rabies' in Mumbai 72
05-Sep-2023 - New partnership working on solutions to combat African animal trypanosomiasis 74
17-Aug-2023 - Boehringer Ingelheim to advance survodutide into three global Phase III studies in obesity 75
14-Aug-2023 - Boehringer Ingelheim receives FDA approval for SENVELGO (velagliflozin oral solution): the first oral liquid medication for diabetes in cats 76
20-Jul-2023 - Boehringer Ingelheim Receives FDA Approval for NexGard PLUS (afoxolaner, moxidectin and pyrantel chewable tablets): A Beef-Flavored Soft Chew That Protects Dogs from Internal and External Parasites 76
09-May-2023 - Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases 79
24-Apr-2023 - Boehringer Ingelheim inaugurates largest European development centre for biotechnology 81
29-Mar-2023 - Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth 83
19-Dec-2022 - Boehringer Ingelheim and Click Therapeutics expand their existing Collaboration to develop Prescription Digital Therapeutics for Schizophrenia 85
06-Sep-2022 - Boehringer Ingelheim launches Fencovis, a new vaccine to prevent calf diarrhea 87
14-Jun-2022 - Boehringer Ingelheim and CarthroniX announce partnership to pursue small molecule therapeutics in canine oncology 88
Boehringer Ingelheim International GmbH - Key Deals 89
14-Jun-2022 - Boehringer Ingelheim signs Option to Acquire Trutino Biosciences 89
Appendix 91
Definitions 91
SWOT Analysis 91
PESTLE Analysis 91
Value Chain Analysis 91
ESG Spotlight 91
Research Methodology 92
Disclaimer 93
Contact Us 93


Tables

Table 1: Boehringer Ingelheim International GmbH - Company Facts 7
Table 2: Boehringer Ingelheim International GmbH - Top Executives 9
Table 3: Boehringer Ingelheim International GmbH - Top Executives Biographies 10
Table 4: Boehringer Ingelheim International GmbH - Subsidiaries 13
Table 5: Boehringer Ingelheim International GmbH - Key Joint Ventures 15
Table 6: Boehringer Ingelheim International GmbH - Products 16
Table 7: Boehringer Ingelheim International GmbH - Historic Events 19
Table 8: Boehringer Ingelheim International GmbH - Competing Players 52
Table 9: Competing Players - AstraZeneca Plc - Key Company Facts 53
Table 10: Competing Players - AstraZeneca Plc - Key Financials 54
Table 11: Competing Players - GSK plc - Key Company Facts 55
Table 12: Competing Players - GSK plc - Key Financials 56
Table 13: Competing Players - Novartis AG - Key Company Facts 57
Table 14: Competing Players - Novartis AG - Key Financials 58
Table 15: Competing Players - Pfizer Inc. - Key Company Facts 59
Table 16: Competing Players - Pfizer Inc. - Key Financials 60
Table 17: Competing Players - Sanofi SA - Key Company Facts 61
Table 18: Competing Players - Sanofi SA - Key Financials 62


Charts

Figure 1: Boehringer Ingelheim International GmbH - SWOT Analysis 30
Figure 2: Boehringer Ingelheim International GmbH - PESTLE Analysis 41
Figure 3: Competing Players - AstraZeneca Plc - Key Financials 54
Figure 4: Competing Players - GSK plc - Key Financials 56
Figure 5: Competing Players - Novartis AG - Key Financials 58
Figure 6: Competing Players - Pfizer Inc. - Key Financials 60
Figure 7: Competing Players - Sanofi SA - Key Financials 62

  • Not Sure / Need Reassuring
    • Confirm Content
      • Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:

        Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.

        Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.

        Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.

    • Sample Pages
      • With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.

        It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.

        To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Check for Alternatives
      • Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.

        To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.

  • Prices / Formats / Delivery
    • Prices
      • All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.

        Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Discounts
      • As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.

        Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.

        To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Available Currencies
      • Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.

        Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.

        To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.

    • Licenses
      • License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Global Site License
      • The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.

        It is important to note that this may exclude Parent Companies or Subsidiaries.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Formats
      • The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.

        If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.

    • Delivery
      • Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.

        Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.

        If a delay in delivery is expected you will be informed about it immediately.

    • Shipping Charges
      • As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.

        If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.

  • Ordering
    • By Credit Card
      • We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.

        Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.

        For more information on PayU please visit: https://www.payu.pl/en/about-us

    • By Money Transfer
      • If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.

        With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.

  • Security
    • Website security
      • We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.

        Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.

    • Credit Card Security
      • We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.

        PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.

PLEASE SELECT LICENSE